Published February 14, 2026 | Version v1
Journal article Open

AN ADVANCED COMPARATIVE EVALUATION OF ATORVASTATIN CALCIUM TABLET BRANDS AVAILABLE IN THE MALAYSIAN MARKET THROUGH COMPREHENSIVE QUANTITATIVE AND QUALITATIVE ANALYSES OF THEIR EFFICACY, SAFETY PROFILES, FORMULATION QUALITY

Authors/Creators

  • 1. Faculty of Pharmacy, AIMST University, Malaysia.

Description

Introduction: Atorvastatin calcium is one of the most prescribed members of its class for the treatment of hyperlipidemia. Currently, there are various brands of atorvastatin calcium tablets available in the Malaysian market and the performance of each may vary, leading to patients questioning the interchangeability between innovator and generics. Objectives: The main purpose of this study is to assess the quality of different brands of atorvastatin calcium tablets marketed in Malaysia, with emphasis on their dissolution profile, and evaluate their bioequivalence. Method: Innovator brand (coded as A) and five generic brands (coded as B to F) of 20 mg atorvastatin calcium tablets were subjected to in vitro tests for organoleptic characterization, identity, content uniformity, weight variation, thickness, diameter, hardness, friability, disintegration, and dissolution according to procedures described in the monograph. Result: All brands of atorvastatin calcium tablets complied with the specifications of the tests conducted. With regard to dissolution test, all the investigated brands released more than 80% of their drug content in 30 minutes. Brand A displayed the greatest dissolution profile followed by Brand D where both depicted nearly 100% release of atorvastatin calcium within 60 minutes, while Brand F showed the lowest percentage of drug release at 92.94% in the same time frame. Conclusion: The findings support that all the atorvastatin calcium brands under evaluation are of good pharmaceutical quality. Though slight differences exist in the dissolution profile between innovator and generic brands, they are still within the acceptable limits and hence it was determined that these brands could be used interchangeably.

Files

25 WJPSR 2033.pdf

Files (1.6 MB)

Name Size Download all
md5:302d669807fc76972be220c2b623e560
1.6 MB Preview Download

Additional details

References

  • Akinleye, M. O., Idris, O., Nwachukwu, P. N., & Oyetunde, O. O. (2012). Quality of brands of atorvastatin calcium tablets marketed in Lagos, Nigeria. In International Journal of Pharmacy and Pharmacology, 3(10). www.internationalscholarsjournals.org
  • 2. Alkufi, H., Alkanani, A. S., Muhareb, S. H., Alhamidawi, A. K., Shahad, M. A., & Abd, S. H. (2023). Quality Assessment of Brands and Generic in Atorvastatin Tablets Available in Iraq-thi-Qar. Journal of Medical and Health Studies, 4(2). https://doi.org/10.32996/jmhs.2023.4.2.2
  • 3. AlMuhsin, A., Ahad, A., Bin Jardan, Y. A., Raish, M., Ahmad, A., Alkharfy, K. M., & Al-Jenoobi, F. I. (2022). Quality assessment of different brands of atorvastatin tablets available in Riyadh, Saudi Arabia. BMC Pharmacology and Toxicology, 23(1). https://doi.org/10.1186/s40360-022-00598-y
  • 4. Ameer, O. Z. (2023). Release Profile of Branded Atorvastatin Calcium Tablet Relative to Commercially Available Counterpart Generics. Dissolution Technologies, 30(3). https://doi.org/10.14227/DT300323PGC7
  • 5. Ansel, H. C., & Allen, L. V. (2014). Ansel's Pharmaceutical Dosage Form and Drug Delivery Systems (10th ed.). Wolters Kluwer Health.
  • 6. Azman, W., & Ahmad, W. (2024). Annual Report of the Acute Coronary Syndrome (ACS) Registry, 2020-2021. http://www.acrm.org.my/ncvd
  • 7. Carstensen, J. T., & Rhodes, C. T. (Eds.). (2000). Drug Stability, Revised, and Expanded: Principles and Practices (3rd ed.). CRC Press.
  • 8. Davies, J. T., Delfino, S. F., Feinberg, C. E., Johnson, M. F., Nappi, V. L., Olinger, J. T., Schwab, A. P., & Swanson, H. I. (2016). Current and emerging uses of statins in clinical therapeutics: A review. Lipid Insights, 9(1). https://doi.org/10.4137/LPI.S37450
  • 9. Fong, A., Wan Ahmad, W. A., Rosman, A., Mustapha, F., Hussein, Z., Taher, S. W., Shafie, A. A., Khicha, N., Tan, H. H., & Kim, P. (2023). Heart Matters: The Rising Burden of Cardiovascular Disease in Malaysia and Potential Touchpoints for Interventions.
  • 10. Gibson, C. M., Pride, Y. B., Hochberg, C. P., Sloan, S., Sabatine, M. S., & Cannon, C. P. (2009). Effect of Intensive Statin Therapy on Clinical Outcomes Among Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. Journal of the American College of Cardiology, 54(24). https://doi.org/10.1016/j.jacc.2009.09.010
  • 11. Hambisa, S., Belew, S., & Suleman, S. (2019). In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, SouthWest Ethiopia. Drug Design, Development and Therapy, 13. https://doi.org/10.2147/DDDT.S189524
  • 12. Institute for Public Health Ministry of Health Malaysia. (2024). National Health and Morbidity Survey (NHMS) 2023:Non-communicable Diseases and Healthcare Demand - Key Findings.
  • 13. Iyzati, A., Shanizza, A., Fakri, A., Aziz, A., Ashari, F., & Su'aidah Nasarudin, S. N. (2024). Malaysian Statistics on Medicines 2018-2022 A publication of the Pharmaceutical Services Programme Ministry of Health Malaysia. www.pharmacy.gov.my
  • 14. Jung, E., Kong, S. Y., Ro, Y. S., Ryu, H. H., & Shin, S. Do. (2022). Serum Cholesterol Levels and Risk of Cardiovascular Death: A Systematic Review and a Dose-Response Meta-Analysis of Prospective Cohort Studies. In International Journal of Environmental Research and Public Health, 19(14). https://doi.org/10.3390/ijerph19148272
  • 15. Liao, J. K., & Laufs, U. (2005). Pleiotropic effects of statins. In Annual Review of Pharmacology and Toxicology, 45. https://doi.org/10.1146/annurev.pharmtox.45.120403.095748
  • 16. Lingwood, D., & Simons, K. (2010). Lipid rafts as a membrane-organizing principle. In Science, 327(5961). https://doi.org/10.1126/science.1174621
  • 17. Malik, A. K., Kumar, R., & Heena. (2016). Spectroscopy: Types. Encyclopedia of Food and Health, 64–72. https://doi.org/10.1016/B978-0-12-384947-2.00643-7
  • 18. Malviya, R., Bansal, V., Pal, O. P., & Sharma, P. K. (2010). High performance liquid chromatography: A short review. In Journal of Global Pharma Technology, 2(5).
  • 19. Mehta, J. L. (2004). Statins: Understanding Clinical Use (1st ed.). Saunders.
  • 20. National Pharmaceutical Regulatory Agency. (2024). QUEST3+ Product Search.
  • 21. Nikam, S., Suryawanshi, K., Shinde, N., Suryawanshi, V., & professor, A. (2022). A brief review on principle, instrumentation and analytical parameter of uv spectroscopy. www.ijnrd.org
  • 22. Popy, F. A., Dewan, I., Parvin, M. N., & Ashraful Islam, S. M. (2012). Evaluation of in vitro equivalence for tablets containing the poorly water-soluble compound atorvastatin. Dissolution Technologies, 19(4). https://doi.org/10.14227/DT190412P30
  • 23. Punithavathi, N., Ong, L. M., L Lena, Y. L., & Leekha on behalf of the Storvas Clinical Trial Study Group, S. (n.d.). A Multicenter Study in Malaysia to Determine the Efficacy and Safety of a Generic Atorvastatin.
  • 24. Rohmani, S., Yugatama, A., Suryadi, B. B., Lady, F., Ainurofiq, A., & Prihapsara, F. (2020). Evaluation of compared dissolution profile of Atorvastatin tablets in markets. www.japer.in
  • 25. Schonewille, M., De Boer, J. F., Mele, L., Wolters, H., Bloks, V. W., Wolters, J. C., Kuivenhoven, J. A., Tietge, U. J. F., Brufau, G., & Groen, A. K. (2016). Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice. Journal of Lipid Research, 57(8). https://doi.org/10.1194/jlr.M067488
  • 26. Shi, Q., Chen, J., Zou, X., & Tang, X. (2022). Intracellular Cholesterol Synthesis and Transport. In Frontiers in Cell and Developmental Biology (Vol. 10). https://doi.org/10.3389/fcell.2022.819281
  • 27. Tariq, M. H., Khan, I., Ahmad, B., Raheem, A., & Yasmeen, M. (2014). Evaluation of In-vitro Bioequivalence of Commonly Prescribed Generics of Poorly Water Soluble Drug-Atorvastatin Calcium in Pakistan. Journal of Pharmacy Research, 8(3).
  • 28. Topol, E. J., Califf, R. M., Prystowsky, E. N., Thomas, J. D., & Thompson, P. D. (Eds.). (2007). Textbook Of Cardiovascular Medicine (3rd ed.). Lippincott Williams & Wikkins.
  • 29. Ulla, M. R. (2018). Comparative assessment of different marketed brands of atorvastatin tablets in Asir region, Saudi Arabia. MOJ Drug Design Development & Therapy, 2(1). https://doi.org/10.15406/mojddt.2018.02.00023
  • 30. United States Pharmacopoeia - National Formulary. (2024a). 〈1216〉 Tablet Friability. https://doi.org/10.31003/USPNF_M99935_02_01
  • 31. United States Pharmacopoeia - National Formulary. (2024b). 〈701〉 Disintegration. https://doi.org/10.31003/USPNF_M99460_03_01
  • 32. United States Pharmacopoeia - National Formulary. (2024c). 〈711〉 Dissolution. https://doi.org/10.31003/USPNF_M99470_03_01
  • 33. United States Pharmacopoeia - National Formulary. (2024d). 〈905〉 Uniformity of Dosage Units. https://doi.org/10.31003/USPNF_M99694_03_01
  • 34. United States Pharmacopoeia - National Formulary. (2024e). Atorvastatin Calcium Tablets. https://doi.org/10.31003/USPNF_M6340_10_01
  • 35. Van Meer, G., Voelker, D. R., & Feigenson, G. W. (2008). Membrane lipids: Where they are and how they behave. In Nature Reviews Molecular Cell Biology (Vol. 9, Issue 2). https://doi.org/10.1038/nrm2330
  • 36. Vogel, A. I., Mendham, J., Denny, R. C., Barnes, J. D., & Thomas, M. J. K. (2000). Vogel's Textbook of Quantitative Chemical Analysis (6th ed.). Prentice Hall.
  • 37. Wan Ahmad, W. A., Rosman, A., Bavanandan, S., Mohamed, M., Abdul Kader, M. A. S., Muthusamy, T. S., Lam, K. H., Kasim, S. S., Hoo, F. K., Fegade, M., Looi, Z. L., & Abdul Rahman, A. R. (2023). Current Insights on Dyslipidaemia Management for Prevention of Atherosclerotic Cardiovascular Disease: A Malaysian Perspective. In Malaysian Journal of Medical Sciences, 30(1): 67–81. Penerbit Universiti Sains Malaysia. https://doi.org/10.21315/mjms2023.30.1.6
  • 38. Waters, D. D. (2009). Clinical Insights From the Treating to New Targets Trial. Progress in Cardiovascular Diseases, 51(6). https://doi.org/10.1016/j.pcad.2009.01.001
  • 39. Windriyati, Y. N., Arifin, I., Lailatunnafiah, & Farikhah, A. (2024). Comparative Dissolution Study of Atorvastatin Calcium Tablets in Indonesia. Dissolution Technologies, 31(1): 17–22. https://doi.org/10.14227/DT310124PGC17
  • 40. World Heart Federation. (2023). World Heart Report 2023: Confronting The World's Number One Killer.
  • 41. Ye, Y. C., Zhao, X. L., & Zhang, S. Y. (2015). Use of atorvastatin in lipid disorders and cardiovascular disease in chinese patients. In Chinese Medical Journal, 128(2). https://doi.org/10.4103/0366-6999.149226
  • 42. Yu Cai Lim, M., & Kiat Ho, H. (2024). Pharmacological modulation of cholesterol 7α-hydroxylase (CYP7A1) as a therapeutic strategy for hypercholesterolemia. In Biochemical Pharmacology, 220. https://doi.org/10.1016/j.bcp.2023.115985
  • 43. Zhang, X., Xing, L., Jia, X., Pang, X., Xiang, Q., Zhao, X., Ma, L., Liu, Z., Hu, K., Wang, Z., & Cui, Y. (2020). Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials. In Cardiovascular Therapeutics, 2020. https://doi.org/10.1155/2020/3987065